Akoya Biosciences Appoints Joseph Driscoll as Chief Financial Officer

MENLO PARK, Calif.–Akoya Biosciences, Inc., today announced the appointment of Joseph Driscoll as Chief Financial Officer. Mr. Driscoll joins Akoya with more than 30 years of financial leadership experience and a proven track record of driving growth and increasing company valuations.

“I am delighted to welcome Joe to the Akoya team and look forward to working with him,” said Brian McKelligon, Chief Executive Officer of Akoya. “Joe’s strategic, finance, and business operations skill set will be a great asset as we continue building on our mission to revolutionize the tissue biomarker field.”

Mr. Driscoll is a seasoned financial and strategic leader with extensive experience in several industries including technology, life sciences, and consumer products. He most recently served as CFO at Quanterix Corporation (NASDAQ: QTRX), where during his tenure the company successfully completed an IPO, and the valuation increased from approximately $200 million to over $500 million in two years. He also served as CFO at several other public and private companies, including Verscend, Inc. (healthcare data analytics), PC Connection, Inc. (technology service provider; NASDAQ: CNXN), Summer Infant, Inc., ACT Electronics, Inc., and Safety 1st, Inc. In addition, Mr. Driscoll held senior management positions at Staples, Inc., and he started his career as an Audit Manager of KPMG Peat Marwick. Mr. Driscoll is a Certified Public Accountant and holds a B.S. in Accounting from Boston College.

“With their comprehensive solutions for high-parameter tissue analysis, Akoya has the opportunity to drive significant advances in biomedical research and I am excited to be joining the company,” said Mr. Driscoll. “Akoya’s recent accomplishments and successes are impressive, and I’m looking forward to joining the rest of the experienced management team to drive the company’s continued growth.”

Akoya recently announced the commercial release of two new products (see press release), the CODEX platform and Phenoptics 2.0, that together form the most complete solution for high-parameter tissue imaging.

About Akoya Biosciences

Akoya Biosciences is committed to developing powerful imaging tools to enable scientists and clinical researchers gain a better understanding of complex diseases such as cancer. The company offers the most comprehensive end-to-end solution for high-parameter tissue analysis from discovery through clinical and translational research, enabling more precise therapies for immuno-oncology and other drug development applications. Akoya’s CODEX platform enables the assessment of more than 40 markers and is ideally suited for biomarker discovery. The company’s Phenoptics platform provides the assay robustness and throughput necessary for translational and clinical research required in clinical trials. For more information, please visit https://www.akoyabio.com/.


Nicole Litchfield
Bioscribe, Inc.
Michelle Linn
Bioscribe, Inc.